Multivessel Coronary Artery Disease
Conditions
Brief summary
The CABG-REVOLUTION study is an investigator-initiated single-arm, multicentre, prospective study for patients with 3-vessel disease (with or without left-main involvement) referred to CABG treatment. Surgical revascularization strategy and treatment planning will be solely based on MSCT (with FFRCT) without knowledge of the anatomy defined by conventional cine-angiography.
Detailed description
The CABG-REVOLUTION study is an investigator-initiated single-arm, multicentre, prospective study for patients with 3-vessel disease (with or without left-main involvement) referred to CABG treatment. Surgical revascularization strategy and treatment planning will be solely based on MSCT (with FFRCT) without knowledge of the anatomy defined by conventional cine-angiography. One clinical follow-up visit including MSCT acquisition will be performed at 30 days after bypass surgery in order to assess graft patency and adequacy of the revascularization with respect to the surgical planning based on non-invasive imaging.
Interventions
RADIATIONMulti-sliced computed tomography (MSCT)
Surgery planning done based solely on MSCT.
Sponsors
GE Healthcare
HeartFlow, Inc.
ECRI bv
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient referred to CABG treatment (as assessed by 'conventional Heart Team'); 2. Patients with at least 1 stenosis (visually determined de novo lesions with ≥50% DS) in all 3 major epicardial territories (LAD and/or side branch, CX and/or side branch, RCA and/or side branch) supplying viable myocardium with or without left main involvement; 3. Patients with hypoplastic right coronary artery (RCA) with absence of descending posterior and presence of a lesion in the LAD and circumflex (CX)territories may be included in the trial as a 3vessel disease equivalent. Ostial LAD plus ostial left circumflex artery (LCX) may be included in the trial as a Left Main equivalent 4. Distal vessel size should be at least 1.5 mm in diameter as visually assessed in diagnostic angiogram; 5. Patient with silent ischemia, chronic stable angina or stabilized acute coronary syndromes with normalized (stable or decreasing) cardiac biomarker values Note: For patients showing elevated Troponin (cTn) (e.g. non-STEMI patients) at baseline (within 24h pre-CABG) an additional blood sample must be collected prior to the CABG procedure to confirm that: • hs-cTn or Troponin I or T levels are stable, i.e. the value should be within 20% range of the value found in the first sample at baseline, or have dropped • CK-MB and CK levels are within normal range If hs-cTn or Troponin I or T levels are stable or have dropped, or the Creatine kinase-MB (CK-MB) and Creatine kinase (CK) levels are within normal ranges, and the ECG is normal, the patient may be included in the study. 6. All anatomical SYNTAX Scores are eligible; 7. Patient amenable to a MSCT coronary angiography (e.g. no claustrophobia, high heartrate not amenable to beta-blockers, poor renal function, etc., up to discretion of investigator); 8. Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site; 9. The patient agrees to the 1-month follow-up visit including a MSCT coronary angiography.
Exclusion criteria
1. Under the age of 18 years; 2. Unable to give Informed Consent; 3. Known pregnancy at time of enrollment. Female of childbearing potential i.e. who are not surgically sterile or post-menopausal (defined as no menses for 2 years without an alternative cause). Female who is breastfeeding at time of enrollment; 4. Prior percutaneous coronary intervention (PCI) or CABG; history of coronary stent implantation; 5. Evidence of evolving or ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice); 6. Known renal insufficiency (e.g. serum creatinine \>2.5mg/dL, or creatinine clearance ≤30 mL/min), or subject on dialysis, or acute kidney failure (as per physician judgment); 7. Concomitant cardiac valve disease requiring surgical therapy (reconstruction or replacement) and/or aneurysmectomy; 8. Single or two-vessel disease (at time of the conventional Heart Team consensus); 9. Non-graftable distal bed in \>1 vessel as assessed by the surgeon based on conventional angiography; 10. Atrial fibrillation or significant arrhythmias; 11. Known allergy to iodinated contrast; 12. A Body Mass Index (BMI) of 35 or greater; 13. Currently participating in another trial and not yet at its primary endpoint.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients in the intention to treat (ITT) population for whom CABG planning and execution was based solely on MSCT. | 2 weeks after enrollment |
| Number of graft/anastomoses for which graft/anastomosis stenosis (≥50%DS - 99%DS) or occlusion (100%DS) occurred as percentage of the total number of intra graft/anastomoses. | 1 month after surgery |
Countries
Belgium, Germany, Italy, Switzerland
Outcome results
None listed